Want to see TRAW full AI Analyst Report?
Top Page
Traws Pharma
(NASDAQ:TRAW)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.43
▼(-28.83% Downside)
Action:Reiterated
Date:08/27/26
TRAW scores low primarily due to weak financial performance (ongoing losses, heavy cash burn, negative equity, and questionable earnings quality in 2025). Technicals also point to a bearish longer-term trend, and valuation metrics provide limited support (negative P/E, no dividend). Corporate events are mixed but include meaningful listing-risk and dilution overhangs.
Positive Factors
Debt-Free Balance Sheet
No debt reduces refinancing and solvency pressure, giving management greater flexibility while clinical programs progress. This avoids interest obligations and limits creditor risk, although the benefit is moderated by negative equity and the company’s continuing need for external capital.
Negative Factors
Persistent Cash Burn
Consistently negative operating and free cash flow indicates that the business is not yet self-funding and must rely on external capital to continue operations. The sharp 2025 deterioration increases financing dependence and can constrain investment in clinical programs over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
No debt reduces refinancing and solvency pressure, giving management greater flexibility while clinical programs progress. This avoids interest obligations and limits creditor risk, although the benefit is moderated by negative equity and the company’s continuing need for external capital.
Read all positive factors
Traws Pharma (TRAW) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.84M
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-100.00%
EPS Growth83.59%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding15,368,277
10 Day Avg. Volume250,709
30 Day Avg. Volume1,102,272
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue3.06
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$1.00Price Target Upside66.67% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.43
Revenue Forecast (FY)N/A
Traws Pharma Business Overview & Revenue Model
Company Description
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includ...
Traws Pharma Earnings Call Summary
Earnings Call Date:Apr 15, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Neutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.Positive Updates
Completed $60 million Private Financing
Announced a private financing providing up to $60.0M in potential gross proceeds (including $10M upfront). Structure includes milestone-based Series A ($10M), Series B ($10M) and a Series C common warrant ($30M, 3-year term) with an accelerated feature if stock trades at 2x the deal price for 30 consecutive days.
Negative Updates
FDA IND Clinical Hold Due to Toxicology Concerns
FDA placed the Investigational New Drug (IND) filing on clinical hold over toxicology data package concerns. Company plans to repeat/submit additional assays and engage FDA; this creates a material risk of delay for U.S. development with a target to advance in the U.S. in late 2026 only if resolved.
Read all updates
Q4-2025 Updates
Positive
Negative
Completed $60 million Private Financing
Announced a private financing providing up to $60.0M in potential gross proceeds (including $10M upfront). Structure includes milestone-based Series A ($10M), Series B ($10M) and a Series C common warrant ($30M, 3-year term) with an accelerated feature if stock trades at 2x the deal price for 30 consecutive days.
Read all positive updates
Company Guidance
Management's guidance and milestones from the call were specific and metric‑heavy: the company completed a private financing providing up to $60.0M in potential gross proceeds (including $10.0M upfront plus three warrants: Series A $10.0M exercisable on MHRA approval to run the challenge trial; Series B $10.0M exercisable after shareholder approval and announcement of challenge data; and a Series C common warrant with a 3‑year term for up to $30.0M if exercised), with the Series C having an accelerated feature if the stock trades at 2× the $1.67 deal price for 30 consecutive days (10‑day forced exercise window); management believes cash including net proceeds and fully‑exercised milestone warrants is sufficient to fund planned expenses into Q1 2027. Financials cited: cash, cash equivalents and short‑term investments of ~$3.8M as of 12/31/2025 (vs $21.3M at 12/31/2024), FY2025 revenue $2.8M (vs $0.226M in 2024), net income $9.2M (or $0.83 basic / $0.82 diluted per share) vs a $166.5M loss ($35.21/share) in 2024, R&D expense $12.1M (vs $12.8M), G&A $8.5M (vs $12.3M), and acquired IPR&D $0 (vs $117.5M). Clinical and development guidance: initiate a UK human challenge prophylaxis trial at hVIVO starting in June pending MHRA review (30‑day clock), complete a Phase I bridging study in Australia to confirm a ~30% increase in exposure with the new compressed tablet (prior data showed plasma >EC90 for >3 weeks and a 28‑day coverage target), while the IND submitted in January is on clinical hold by FDA for toxicology issues that the company is addressing with an objective to resume U.S. development in late 2026.Traws Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.73M | 2.79M | 226.00K | 226.00K | 226.00K | 226.00K |
| Gross Profit | 2.73M | 2.79M | 214.00K | 226.00K | 226.00K | 226.00K |
| EBITDA | -15.47M | -17.81M | -166.51M | -20.28M | -19.61M | -16.48M |
| Net Income | -11.41M | 9.17M | -54.67M | -18.95M | -18.96M | -16.16M |
Balance Sheet | ||||||
| Total Assets | 8.16M | 10.62M | 24.96M | 22.68M | 39.37M | 55.48M |
| Cash, Cash Equivalents and Short-Term Investments | 3.13M | 3.82M | 21.34M | 20.82M | 38.76M | 55.07M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 13.47M | 11.25M | 56.59M | 12.01M | 11.06M | 9.36M |
| Stockholders Equity | -5.31M | -629.00K | -31.63M | 10.67M | 28.31M | 46.12M |
Cash Flow | ||||||
| Free Cash Flow | -11.31M | -20.77M | -29.79M | -17.95M | -16.29M | -19.49M |
| Operating Cash Flow | -11.31M | -18.18M | -29.79M | -17.93M | -16.29M | -19.49M |
| Investing Cash Flow | 0.00 | -2.58M | -3.65M | -14.00K | 0.00 | 0.00 |
| Financing Cash Flow | 5.15M | 3.20M | 33.98M | 0.00 | 0.00 | 55.56M |
Traws Pharma Technical Analysis
Negative
0.60
Price Trends
0.54
Negative
0.75
Negative
1.24
Negative
Market Momentum
-0.02
Positive
35.16
Neutral
6.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAW, the sentiment is Negative. The current price of 0.6 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.54, and below the 200-day MA of 1.24, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 35.16 is Neutral, neither overbought nor oversold. The STOCH value of 6.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRAW.
Traws Pharma Risk Analysis
Traws Pharma disclosed 50 risk factors in its most recent earnings report. Traws Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Traws Pharma Peers Comparison
UnderperformOutperform
Sector (51)
TRAW
Traws Pharma
0.45
-2.46
-84.66%
LSTA
Lisata Therapeutics
1.06
-1.37
-56.38%
LEXX
Lexaria Bioscience
3.32
-10.23
-75.49%
APLM
Apollomics
21.50
3.07
16.66%
Traws Pharma Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Traws Pharma Reports Q2 Results, Influenza Program Advances
Neutral
Aug 14, 2026
On August 14, 2026, Traws Pharma reported second-quarter 2026 results and business updates, highlighting progress on its lead influenza program, tivoxavir marboxil, and recent financing activities. The company is preparing a revised toxicology pac...
Delistings and Listing ChangesRegulatory Filings and Compliance
Traws Pharma Receives Nasdaq Minimum Bid Price Notice
Negative
Jul 31, 2026
On July 29, 2026, Traws Pharma received a notice from Nasdaq that its common stock had closed below $1.00 per share for at least 30 consecutive business days, placing the company out of compliance with Nasdaq’s minimum bid price rule. The no...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.